A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Enzon Pharmaceuticals, Inc. (together with its subsidiaries, the “Company,” “Enzon,” “we” or “us”) is positioned as a public company acquisition vehicle. We were incorporated on May 11, 1983. Historically, we have received royalty revenues from licensing arrangements with other companies primarily related to sales of certain drug products that utilized Enzon’s proprietary technology. For more than ten years, we have had no clinical operations and limited corporate operations. We previously were a party to a marketing agreement relating to the drug Vicineum, which, if approved, could have potentially generated milestone and royalty payments to us in the future. However, our licensee for this drug was canceled by the counterparty to the marketing agreement and our patent for Vicineum has since expired. Accordingly, we do not believe any future revenue will be earned from this product or that if any such revenue is earned it will be material.
| Segment | 2021 | % of Total |
|---|---|---|
Royalty | $0M | 100% |
| Metric | TTM | FY2025 | FY2024 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -5.5M | -5.5M | -497K | -1.5M | -2.5M | -1.8M |
| EPS | $-0.07 | $-0.07 | $-0.01 | $-0.02 | $-0.03 | $-0.03 |
| Free Cash Flow | -3.0M | -3.0M | 1.1M | -659K | -501K | -380K |
| ROIC | -9.8% | -9.8% | -34.9% | -23.9% | -7.6% | -14.0% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | -17.96 | 14.68 | 12.97 | 8.81 | 5.55 |
| Dividends/Share | $0.02 | $0.02 | $0.03 | - | $0.00 | $0.12 |
| Operating Income | -5.3M | -5.3M | -1.3M | -1.0M | -469K | -1.3M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | 0.0% | -2291.1% | -16.5% | -35.3% | -40.8% | -26.4% |
| Shares Outstanding | 79M | 79M | 50M | 73M | 83M | 59M |
ENZON PHARMACEUTICALS, INC. passes 1 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 2.7x vs a median of 1.4x. Total shareholder yield (dividends) is 26.9%. At current prices, the estimated annualized return to fair value is -23.1%.
ENZON PHARMACEUTICALS, INC. (ENZN) has a 5-year average return on invested capital (ROIC) of -18.0%. This is below average and may indicate limited pricing power.
ENZON PHARMACEUTICALS, INC. (ENZN) has a market capitalization of $5M. It is classified as a small-cap stock.
Yes, ENZON PHARMACEUTICALS, INC. (ENZN) pays a dividend with a trailing twelve-month yield of 26.88%.
ENZON PHARMACEUTICALS, INC. (ENZN) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
ENZON PHARMACEUTICALS, INC. (ENZN) generated $-3 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
ENZON PHARMACEUTICALS, INC. (ENZN) reported earnings per share (EPS) of $-0.07 in its most recent fiscal year.
ENZON PHARMACEUTICALS, INC. (ENZN) has a return on equity (ROE) of -2291.1%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 16 years of financial data for ENZON PHARMACEUTICALS, INC. (ENZN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ENZON PHARMACEUTICALS, INC. (ENZN) has a book value per share of $-0.03, based on its most recent annual SEC filing.